Business Context and Reporting Period
This Form 8-K was filed by OncoGenex Pharmaceuticals, Inc. on June 13, 2017. The filing announces a special meeting of stockholders scheduled for August 1, 2017, to vote on a proposed merger with Achieve Life Sciences, Inc. The registrant is incorporated in Delaware and maintains its principal executive offices in Bothell, Washington.
Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events regarding the proposed merger.
Material Changes
- Merger Announcement: A special stockholder meeting is set for August 1, 2017, at 9:00 a.m. Pacific Time in Seattle, Washington, to vote on the merger with Achieve Life Sciences, Inc.
- Record Date: Stockholders of record as of the close of business on June 13, 2017, are entitled to vote.
- Regulatory Status: The Form S-4 registration statement (File No. 333-216961) containing the proxy statement/prospectus/information statement was declared effective by the SEC on June 13, 2017.
Guidance, Outlook, and Risks
Management urges stockholders to read the final proxy statement/prospectus/information statement carefully before making a decision on the merger. The filing notes that OncoGenex and Achieve, along with their respective executive officers and directors, are deemed participants in the solicitation of proxies. Information regarding their interests in the proposed merger is detailed in the final proxy statement filed on June 13, 2017. The communication explicitly states it does not constitute an offer to sell or a solicitation of an offer to buy securities.
Key Facts for Investor Verification
- Verify the final proxy statement/prospectus/information statement for details on the merger terms and executive interests.
- Confirm stockholder record date eligibility (June 13, 2017) for voting rights.
- Review the Form S-4 (File No. 333-216961) for comprehensive transaction details.
- Note that the merger vote is scheduled for August 1, 2017.